TO
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Chrono-immunotherapy as a low-hanging fruit for cancer treatment ? A call for pragmatic randomized clinical trials | Journal for immunotherapy of cancer |  | 2025 | 3 | 8 | ||
| LUNAR : Full Moon or Eclipse ? An exploration into tumor treating fields in lung cancer | Translational oncology | | 2025 | 23 | 64 | ||
| How many people in the US are eligible for and respond to checkpoint inhibitors : An empirical analysis | International journal of cancer | | 2025 | 23 | 7 | ||
| Case Report : Organ procurement in a DCD donor with ovarian thecoma : abdominal NRP enabled timely and safe resection, pathological confirmation, and successful kidney transplantation | Frontiers in transplantation | | 2025 | 1 | 0 | ||
| Oncologie. Conjugués anticorps-médicaments : une avancée pleine de défis | Revue médicale suisse |  | 2025 | 38 | 0 | ||
| Cisplatin shortage results in substitution of more expensive treatments : Drug cost analysis | European journal of cancer | | 2024 | 25 | 40 | ||
| Health-related quality of life in trials with high rates of early censoring : Caution advised | European journal of cancer | | 2024 | 48 | 66 | ||
| Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas : Looking Forward to What Is Next | Journal of clinical oncology | | 2024 | 12 | 32 | ||
| When destiny doesn't pan out : Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan | Cancer | | 2024 | 28 | 0 | ||
| Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review | Journal of thoracic oncology | | 2024 | 151 | 664 | ||
| Equal censoring but still informative : When the reasons for censoring differ between treatment arms | European journal of cancer | | 2024 | 81 | 61 | ||
| Interpréter un essai randomisé en oncologie : éléments clés en clinique | Revue médicale suisse | | 2024 | 84 | 10 | ||
| Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials | European journal of cancer | | 2024 | 88 | 128 | ||
| Are Blood-Based Cancer Screening Tests Ready for Primetime ? | The American journal of medicine | | 2024 | 30 | 66 | ||
| A novel framework to assess haematology and oncology registration trials : The THEOREMM project | European journal of clinical investigation | | 2024 | 80 | 72 | ||
| Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia : Critical analysis of the ASC4FIRST trial | American journal of hematology | | 2024 | 14 | 15 | ||
| Neoadjuvant followed by adjuvant pembrolizumab in melanoma : time biases in the data analysis of the SWOG S1801 trial | Translational oncology | | 2024 | 65 | 81 | ||
| Shrinking sample sizes in lung cancer trials : Various explanations, open questions | European journal of cancer | | 2024 | 16 | 0 | ||
| Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials : A Systematic Review | JAMA oncology | | 2024 | 37 | 43 | ||
| Bedside implications of the use of surrogate endpoints in solid and haematological cancers : implications for our reliance on PFS, DFS, ORR, MRD and more | BMJ oncology | | 2024 | 19 | 16 | ||
| CDK4/6 inhibitors as adjuvant therapy in early breast cancer ? Uncertain benefits, guaranteed harms | European journal of cancer | | 2024 | 75 | 163 | ||
| The fate of sotorasib : a regulatory failure potentially harming patients | Lancet. Oncology | | 2024 | 41 | 88 | ||
| Qualitative assessment of the control arm in oncology randomized clinical trials | | 2024 | 171 | 462 | |||
| Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity | JAMA network open | | 2023 | 58 | 11 | ||
| Cost of drug wastage from dose modification and discontinuation of oral anticancer drugs | JAMA oncology | | 2023 | 73 | 14 | ||
| Voyage de nuit | Revue médicale suisse | | 2023 | 98 | 16 | ||
| Quality of life in the adjuvant setting : a meta-analysis of us food and drug administration approved anti-cancer drugs from 2018 to 2022 | Journal of cancer policy | | 2023 | 57 | 20 | ||
| Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer | BMC medicine | | 2023 | 75 | 78 | ||
| The definition of long COVID used in interventional studies | European journal of clinical investigation | | 2023 | 49 | 0 | ||
| Cancer drug price and novelty in mechanism of action | JAMA network open | | 2023 | 229 | 119 | ||
| Molecular testing to deliver personalized chemotherapy recommendations : risking over and undertreatment | BMC medicine | | 2022 | 57 | 50 | ||
| The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy | European journal of cancer | | 2021 | 86 | 0 | ||
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | 2021 | 69 | 91 | ||
| Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer | Clinical Cancer Research | | 2018 | 526 | 1 | ||
| Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | | 2016 | 458 | 0 |
